Caplin Steriles gets USFDA approval for Sumatriptan Injection

Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 6 mg/0.5 mL (12 mg/mL) Single dose Vials, a generic therapeutic equivalent version of (RLD), IMITREX Injection, of GlaxoSmithKline, USA.

Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache. According to IQVIATM (IMS Health), Sumatriptan Injection had US sales data of approximately $5 million for the 12-month period ending March 2021, for Vial presentation.

Shares of CAPLIN POINT LABORATORIES LTD. was last trading in BSE at Rs.691 as compared to the previous close of Rs. 689.5. The total number of shares traded during the day was 15754 in over 1538 trades.

The stock hit an intraday high of Rs. 702.95 and intraday low of 686. The net turnover during the day was Rs. 10936557.

Source : Equity Bulls

Keywords